Telix Pharmaceuticals Limited: Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) announces that the Biogenix Molecular Research Center ...
Future Market Insights6h
Global PARP Inhibitor Market Poised for Explosive Growth, Surpassing USD 16,153.50 Million by 2034 amid Rising Cancer Burden | FMI
According to recent market analysis, the global PARP inhibitor market, valued at USD 6,279.90 million in 2024, is set to witness exceptional growth, reaching USD 16,153.50 million by 2034. This ...